| FDA Clears Software Product Release by Endocardial Solutions
December 1, 1999 MINNEAPOLIS / ST.PAUL -- Endocardial Solutions, Inc. (Nasdaq: ECSI) today announced that the U.S. Food and Drug Administration has cleared release of a new version of the company's software product. The new version is an upgrade for use in the company's EnSite 3000® System for diagnostic mapping of complex arrhythmias. This software version gives the electrophysiolgist a number of features to improve arrhythmia analysis. It is designed to enhance both performance and navigational ability of the EnSite 3000® System. It will also help Endocardial Solutions in training hospital staff and provide electrophysiologists better capability in making clinical presentations. "This is good news for our U.S. market," said Jim Bullock, president and CEO. "This software version was cleared in Canada and Europe earlier this fall, and it has been released in both markets. Development of our next-generation software will be completed at the end of this year and is expected to be released to the market in mid-2000. This software will further improve diagnosis of arrhythmias and efficiency in training hospital staff." The U.S. Food and Drug Administration cleared the EnSite 3000® System for use in diagnostic mapping of complex arrhythmias in the right atrium of the heart during the second quarter 1999. Through a distribution agreement with Medtronic, Inc., the EnSite 3000® System and catheter are available in full market release to electrophysiologists in Europe. <*dv_3*>Based in St. Paul, Minnesota, Endocardial Solutions (www.endocardial.com) develops, manufactures and markets technology for diagnostic mapping of complex arrhythmias (abnormally rapid heartbeats caused by irregular electrical activity in the heart). The EnSite 3000® System provides a 3D graphical display of the heart's electrical activity. The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. A number of factors should be considered in conjunction with these forward-looking statements. These factors are set forth in the cautionary statements included in Exhibit 99 to Endocardial Solutions' Form 10-Q for the quarter ended September 30, 1999, filed with the Securities and Exchange Commission. Endocardial Solutions cautions investors and others to review the statements set forth in that report and that other factors may prove to be important in affecting the business and results of operations of Endocardial Solutions. Contacts: <*dv_0*>Leota Pearson, VP Finance & CFO, Endocardial Solutions
(651) 523-6933
lpearson@endocardial.com Perry Ketchum, Ketchum Metz Inc.
(763) 479-0145
pketchum@ketchummetz.com | 
